Purpose: Androgen deprivation therapy (ADT) is widely used to treat prostate cancer (PC). However, ADT has been associated with various adverse events (AEs) affecting the liver and kidneys. We aimed to evaluate the risk of liver- and kidney-related AEs after ADT.Materials and Methods: This retrospective cohort study used data from the National Health Insurance Database of Korea from 2007 to 2022 and included patients diagnosed with PC between 2013 and 2017. Patients who received ADT were matched 1:1 with those who did not using propensity score matching in the liver and kidney cohorts. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).Results: The study included 9,877 and 16,834 patients in the liver and kidney cohorts, respectively. The risk of hepatitis was higher among ADT users (adjusted HR aHR, 1.27; 95% CI, 1.04–1.54), and the risk was even greater among patients aged ≥70 years (aHR, 1.37; 95% CI, 1.09–1.72). Longer ADT duration was associated with an increased risk of hepatitis (aHR, 1.32; 95% CI, 1.06–1.65). ADT use was not significantly associated with the risk of acute kidney injury (AKI) or chronic kidney disease (CKD) (AKI: aHR, 1.22; 95% CI, 0.92–1.64; CKD: aHR, 1.16; 95% CI, 0.97–1.38).Conclusion: In patients with PC, ADT, particularly when used for an extended duration, was associated with an increased risk of hepatitis, but not with kidney-related AEs. Close monitoring for liver AEs is recommended in patients undergoing long-term ADT.
Yun et al. (Thu,) studied this question.